Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Genitourinary 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Thymoma 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Radiation Pneumonitis 1Pneumonia 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Melanoma 1Lung Diseases, Interstitial 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colitis 1Carcinoma, Renal Cell 1Advanced Squamous Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 92Nivolumab 57Cyclophosphamide 22Ipilimumab 17atezolizumab 15Magnetic Resonance Spectroscopy 14Specimen Handling 13Radiosurgery 13Paclitaxel 13Interleukin-2 12Docetaxel 12fludarabine 11Carboplatin 11Pemetrexed 10spartalizumab 9Biopsy 9durvalumab 8Cisplatin 8Radiotherapy 7Immune Checkpoint Inhibitors 7Blood Specimen Collection 7cemiplimab 6avelumab 6aldesleukin 6Taxes 6Gemcitabine 6Drug Therapy 6Bevacizumab 6trametinib 5tislelizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Prednisone × Thoracic × Clear all
NCT02763761 2018-10-09

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Bristol-Myers Squibb

Phase 2 Withdrawn
DermatologicGenitourinaryThoracic

Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡